Zoetis Study Shows Simparica Trio Outperforms NexGard Plus Against Drug-Resistant Heartworm
Event summary
- Zoetis' Simparica Trio protected 3x more dogs from infection with a resistant heartworm isolate than NexGard Plus in a head-to-head study.
- The study, published in Parasites & Vectors, involved 24 dogs experimentally challenged with the ML-resistant Dirofilaria immitis ZoeLA isolate.
- Simparica Trio delivered a higher moxidectin dosage (24 µg/kg) compared to NexGard Plus (12 µg/kg), resulting in significantly lower heartworm counts.
- No Simparica Trio-treated dogs had detectable microfilariae at the study's end, compared to 13% of NexGard Plus-treated dogs.
The big picture
The study underscores the growing challenge of drug-resistant heartworm, a trend that threatens the efficacy of existing preventives. Zoetis' higher-dosage formulation of moxidectin in Simparica Trio could set a new standard for heartworm prevention, particularly in regions where resistance is emerging. The findings may also pressure competitors to adjust their formulations or dosing strategies.
What we're watching
- Market Differentiation
- How Zoetis will leverage these findings to position Simparica Trio against NexGard Plus in regions with drug-resistant heartworm.
- Regulatory Impact
- Whether the study results will influence veterinary guidelines for heartworm prevention in areas with resistant isolates.
- Product Adoption
- The pace at which veterinarians and pet owners shift to higher-dosage moxidectin preventives like Simparica Trio.
Related topics
